Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2025-10-28 Regulatory Filings
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
Regulatory Filings Classification · 100% confidence The document is a press release announcing the initiation of a Phase 1/2a clinical trial for a new drug candidate (MDX2004) by ModeX Therapeutics, a subsidiary of OPKO Health. It details the drug's mechanism, the trial's purpose, and mentions upcoming poster presentations at a medical conference. It does not fit into financial reporting categories like 10-K or IR, nor is it a regulatory filing or a report publication announcement. As it is a general corporate announcement regarding business operations and R&D progress, it falls under the 'Regulatory Filings' (RNS) category as the fallback for miscellaneous corporate announcements.
2025-10-28 English
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers
Regulatory Filings Classification · 95% confidence The document is a short regulatory filing (under 2,000 characters) submitted to the Israel Securities Authority via the MAGNA system. It explicitly states 'Attached hereto is a report on...' followed by a filename (20251028PR_isa.pdf), which indicates that this document is an announcement regarding the publication of a report rather than the report itself. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-10-28 English
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Report Publication Announcement Classification · 100% confidence The document is a short announcement (2208 characters) informing the public about the upcoming release of the company's third-quarter 2025 financial results and the scheduling of a conference call. It does not contain the actual financial results, but rather serves as a notification of the event. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2025-10-23 English
OPKO Health to Report Third Quarter 2025 Financial Results on October 29
Report Publication Announcement Classification · 100% confidence The document is a short regulatory filing (1856 characters) that serves as an announcement regarding the upcoming release of financial results. It explicitly states 'Attached hereto is a report on OPKO Health to Report Third Quarter 2025 Financial Results on October 29' and provides a PDF reference. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the financial report itself, making it a Report Publication Announcement (RPA).
2025-10-23 English
Immediate Report
Major Shareholding Notification Classification · 100% confidence The document is a Schedule 13D filing submitted to the U.S. Securities and Exchange Commission (SEC). Schedule 13D is a mandatory disclosure form used to report the acquisition of more than 5% of a company's voting shares by a beneficial owner. This document specifically details the shareholdings of Phillip Frost and associated trusts in OPKO Health, Inc. Since Schedule 13D filings are notifications of significant share ownership levels (crossing thresholds), they fall under the 'Major Shareholding Notification' category.
2025-10-02 English
Immediate Report
Director's Dealing Classification · 95% confidence The document is a short regulatory filing from the Israel Securities Authority (MAGNA system) that serves as a cover sheet for an attached Schedule 13D filing. It explicitly states 'Attached hereto is a report on Schedule 13D Frost' and provides a filename for the attachment. Per the 'Menu vs Meal' rule, since this is a short announcement/cover document for an external report, it is classified as a Report Publication Announcement.
2025-10-02 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.